H. Kusuoka

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study

Y. Ohashi, H. Akaza, S. Horie, 2018, Cancer science.

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

Y. Ohashi, H. Akaza, S. Naito, 2017, Japanese journal of clinical oncology.